The initial reporter stated that a patient received discrepant results when testing with coaguchek xs meter serial number (b)(4).The reporter also believed usage of the device led to the patient having a stroke.On (b)(6) 2020, back to back measurements were performed on the patient using the meter, resulting in values of 1.8 inr and 2.4 inr.On (b)(6) 2020, the patient had a meter result of 4.6 inr.After this measurement, the patient's warfarin medication was held for one day and then the normal dosage was resumed.The patient was admitted to the hospital on (b)(6) 2020 due to a stroke.The patient was hospitalized in the status of acute care.The reporter alleges the 4.6 inr measurement performed on (b)(6) 2020 was incorrect, leading the patient's warfarin dosage to be reduced and that this may have had a role in the patient's stroke.The patient's warfarin medication was increased on (b)(6) 2020 from 2 mg.To 2.5 mg.The patient's normal warfarin dose is 2.0 mg.The patient's warfarin medication was subsequently reduced to 1.5 mg.For one day, but the reporter was unable to specify when this change was made.At the emergency room, the patient had a computerized axial tomography scan and this was inconclusive.The patient received magnetic resonance imaging which confirmed an ischemic stroke occurred affecting the left side of the patient's brain, impacting her ability to communicate, move the fingers in her right hand entirely, and reducing the range of motion in her shoulder joint in the right arm.An examination of the patient's carotid artery was performed, resulting in no findings.The patient was discharged from the hospital and admitted to a rehabilitation facility on either the (b)(6) 2020 or (b)(6) 2020.At the rehabilitation facility, the patient received speech, occupational, and physical therapy.The patient was also experiencing atrial fibrillation.The patient was expected to remain at the rehabilitation facility until (b)(6) 2020.At the rehabilitation facility, the patient's inr is tested daily.The patient was diagnosed with lupus antibodies approximately two or three months prior to (b)(6) 2020.Per product labeling: "the presence of anti-phospholipid antibodies (apas) such as lupus antibodies (la) can potentially lead to prolonged clotting times, i.E., they may cause false-high inr values.If you have or suspect that you have apas, contact your doctor and do not continue inr testing with this device." the therapeutic range was 2.5 - 3.5 inr and the patient's testing interval is weekly.
|
The reporter's meter was provided for investigation where it was tested using retention test strips and retention controls.Testing results (qc range = 4.1 - 6.8 inr): qc 1: 5.0 inr, qc 2: 5.2 inr, qc 3: 5.0 inr.The obtained qc values were in the allowed range of the used combination strip lot - qc lot.All measurements were without error messages.The maximum difference between measurements was 4%.
|